E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of postmenopausal osteoporosis |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine whether AMG 162 treatment can reduce the number of postmenopausal osteoporotic women (BMD T-score below -2.5) with incident new vertebral fractures.
The primary safety objective is to characterize the safety and tolerability profile of AMG 162 in this population based on the adverse event incidence, changes in laboratory profiles, and immunogenicity to AMG 162. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives will be to assess the effect of AMG 162 on time to first non-vertebral fracture and time to first hip fracture. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
- Postmenopausal women, between 60 and 90 years old - BMD T-score < –2.5 at one or more of the following regions: the lumbar spine, total hip, or femoral neck - Ethical - Before any study-specific procedure, the appropriate written informed consent must be obtained
|
|
E.4 | Principal exclusion criteria |
- BMD T-score < -4.0 at one or more of the following regions: Lumbar spine, total hip, or femoral neck - Oral bisphosphonate treatment for osteoporosis: Ineligible if used for 3 or more years cumulatively; If used for >3 months, but ≤ 3 years, at least a one year period since last dose is necessary for eligibility; If used ≤ 3 months at any time in the past, subject is eligible. - Administration of intravenous bisphosphonate, fluoride or strontium for osteoporosis within the last 5 years - Administration of any of the following treatments within the last 6 weeks: a) PTH or PTH derivatives, eg, teriparatide b) Anabolic steroids or testosterone c) Glucocorticosteroids (> 5 mg prednisone equivalent per day for more than 10 days) d) Systemic hormone replacement therapy e) Selective estrogen receptor modulators (SERMs), eg, raloxifene f) Tibolone g) Calcitonin h) Calcitriol - Evidence of any of the following per patient report, chart review, DXA, or X-ray review: a) Hyper or hypothyroidism; patients on stable thyroid treatment with a normal TSH will be allowed b) Current hyper- or hypoparathyroidism c) Current hypocalcemia (albumin adjusted serum calcium below 2.13 mmol/L [8.5 mg/dL]) d) Vitamin D deficiency [(25) hydroxy Vitamin D level < 12 ng/mL) e) Rheumatoid arthritis f) Paget’s disease g) Malignancy (except basal cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years h) Any bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings i) Malabsorption syndrome j) Height, weight and girth which may preclude accurate DXA measurements k) Advanced scoliosis or extensive lumbar fusion which would preclude vertebral fracture assessment l) Any severe or more than 2 moderate vertebral fractures on spinal X-rays (see section 7.9) m) Less than 2 lumbar vertebrae (L1-L4) evaluable for DXA - Known sensitivity to mammalian cell derived drug products - Any organic or psychiatric disorder, or laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results - Evidence of alcohol or substance-abuse within the last 12 months that the investigator believes would interfere with understanding or completing the study - Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures - For biopsy sub study subjects only: known or suspected sensitivity or contraindication to tetracycline derivatives - Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy - The number of subjects with incident new vertebral fractures (Yes/No) during 24 months and subsequently 36 months of treatment. - The time to first non-vertebral fracture during 24 and subsequently 36 months of treatment; - The time to first hip fracture during 24 and subsequently 36 months of treatment.
Safety - Adverse event incidence by system organ class and preferred term - Changes in safety laboratory analytes (serum chemistry, hematology) at each visit - Subject Incidence of anti-AMG 162 antibodies (Yes/No)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 10 |